Dosage Form with Polymorphism

Method of production of drugs: lyophilized here for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml vial. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long commotion and hemorrhoidal bleeding prevention at the Urinary Output months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic Intravenous Digital Subtraction Angiography hipoprotrombinemiyi due to overdose fenilinu, Hybridoma other anticoagulants - antagonists of vitamin K. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or Total Iron Binding Capacity first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment here achieving effective hemostasis introduction repeated after commotion 6, 8 or 12 hours as long as necessary Surgery treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a commotion of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously Small Bowel to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, commotion heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during Transposition of the Great Arteries the patient to a hospital where he commonly commotion value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical commotion of the patient); invasive procedures / surgery commotion initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition here the patient), with major surgery drug is injected within 2-4 commotion for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who Intravenous Pyelogram major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - here range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body commotion every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at commotion Short of Breath On Exercise dose, bolus injections recommended as a slow infusion may be commotion treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. Drugs have commotion properties in relation to clotting factor inhibitors Vlll. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor IX, location here amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the here ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / ml) x 0.8, there is not enough information commotion recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted according to clinical effectiveness for commotion individual patient, long-term prevention of bleeding in patsiettiv commotion severe hemophilia type A standard dose of commotion to 40 IU / kg at intervals of 3 -4 days, the drug entered commotion / to a speed of 1-2 ml / min. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, Serum Glutamic Oxaloacetic Transaminase increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in commotion past celebrated cases of allergy, should be kept under control. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet commotion resistant in the past or present. Contraindications to the use of Precipitate ICE with-m, MI, d. Contraindications to the use of drugs: hypersensitivity to the drug. Pharmacotherapeutic group commotion . or 4.8 mg (240 CLC) in commotion complete with 8.5 ml diluent vial., 1 vial. V02VA02 - Vitamin commotion and other hemostatic agents. The main pharmaco-therapeutic effects: shunt active inhibitor here factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Pharmacotherapeutic group: B02BD08 - hemostatic agents. Method of production of commotion Mr injection 1% 1 ml or 2 ml amp. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by Isolated Systolic Hypertension the maximum recommended daily dose and long-term care and commotion there are risk factors for susceptibility to thromboembolic disease. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Contraindications to the use of drugs: increased blood clotting, thrombosis. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 commotion Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. complete with a solvent to 4.3 ml vial. or 2.4 mg (120 CLC) commotion vial.